Næstved Hospital

At Næstved Hospital the oncology department is advancing peri‑operative care by integrating modern imaging, precision sedation and multimodal pain strategies to support cancer surgery and related procedures.

• Image‑guided tumor biopsies and ablative techniques
• Enhanced recovery pathways with optimized analgesia
• Safety monitoring of anesthesia in high‑risk oncologic patients

The work combines clinical insight with cutting‑edge equipment to improve patient comfort and procedural outcomes.

Researchers at the site are evaluating therapies that reduce the risk of recurrent heart events after a myocardial infarction and exploring novel approaches to manage chronic cardiac conditions.

• Post‑MI outcome measures including revascularization and mortality
• Beta‑blocker and statin regimens in secondary prevention
• Arrhythmia detection using wearable cardiac monitors

These studies aim to lower cardiovascular morbidity in patients who also receive cancer treatment.

The department conducts trials focused on blood‑related malignancies such as multiple myeloma and lymphomas, testing new immunologic combinations and maintenance strategies.

• Combination of monoclonal antibodies with standard chemotherapy
• Maintenance therapy after autologous stem‑cell transplant
• Biomarker‑driven selection of targeted agents

Efforts are directed at prolonging remission and improving quality of life for patients with hematologic cancers.

Trials explore endocrine‑driven cancers, notably hormone‑receptor positive breast cancer and prostate cancer, assessing novel hormonal blockers and supportive care for treatment‑related symptoms.

• CDK4/6 inhibitors combined with endocrine therapy
• Androgen deprivation therapy with next‑generation anti‑androgens
• Management of hot flashes using selective neurokinin‑3 antagonists

The goal is to enhance disease control while mitigating hormonal side effects.

Investigations target malignancies of the prostate and urinary tract, including metastatic castration‑sensitive prostate cancer and urothelial carcinoma, leveraging genomic profiling to guide therapy.

• Targeted agents matched to HRR gene mutations
• Immunotherapy combos for advanced urothelial cancer
• Evaluation of novel androgen receptor degraders

These studies seek to personalize treatment based on molecular characteristics.

The hospital’s orthopedic and oncology teams collaborate on trials for joint degeneration and postoperative recovery, aiming to reduce pain and improve function in patients with cancer‑related musculoskeletal issues.

• Allogenic mesenchymal stem‑cell therapy for knee osteoarthritis
• Temporary discontinuation of SSRIs around hip/knee arthroplasty
• Enhanced rehabilitation protocols after joint replacement

Outcomes focus on mobility, pain relief, and overall quality of life.

A broad portfolio of oncology trials addresses solid tumors such as breast cancer, non‑small cell lung cancer, head‑and‑neck squamous cell carcinoma, and triple‑negative breast cancer, testing targeted therapies, immunotherapies and novel drug combinations.

• Genomic‑guided targeted therapy across multiple tumor types
• Neoadjuvant regimens with added agents to improve pathologic complete response
• Combination immunotherapy trials evaluating progression‑free survival

The overarching aim is to increase survival and achieve durable responses for diverse cancer patients.

Studies at Næstved Hospital evaluate innovative treatments for chronic lung conditions, including severe asthma and chronic obstructive pulmonary disease (COPD), with an emphasis on reducing exacerbations and improving lung function.

• Anti‑IL‑5 therapy (benralizumab) for eosinophilic asthma
• Anti‑TSLP antibody (tezepelumab) to lower COPD flare‑ups
• Triple inhaler combination versus dual bronchodilator therapy on cardiopulmonary outcomes

These investigations aim to provide better symptom control and fewer hospitalizations for respiratory patients.

A selection of trials falls outside the defined therapeutic categories, covering areas such as diagnostic device validation, patient‑reported outcome measures and supportive care interventions.

• Evaluation of new imaging equipment for tumor detection
• Assessment of oral mucositis pain relief with novel topical agents
• Quality‑of‑life surveys for patients undergoing cancer therapy

These projects complement the core oncology program by enhancing diagnostics and symptom management.